588 related articles for article (PubMed ID: 29175587)
1. Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2018 Feb; 76():154-165. PubMed ID: 29175587
[TBL] [Abstract][Full Text] [Related]
2. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2017 Aug; 73():154-169. PubMed ID: 28715754
[TBL] [Abstract][Full Text] [Related]
3. Uses of cyclohexane-1,3-dione for the synthesis of 1,2,4-triazine derivatives as anti-proliferative agents and tyrosine kinases inhibitors.
Megally Abdo NY; Milad Mohareb R; Halim PA
Bioorg Chem; 2020 Apr; 97():103667. PubMed ID: 32087416
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors.
Liu J; Nie M; Wang Y; Hu J; Zhang F; Gao Y; Liu Y; Gong P
Eur J Med Chem; 2016 Nov; 123():431-446. PubMed ID: 27490023
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors.
Li S; Zhao Y; Wang K; Gao Y; Han J; Cui B; Gong P
Bioorg Med Chem; 2013 Jun; 21(11):2843-55. PubMed ID: 23628470
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel 6,7-disubstituted-4-(2-fluorophenoxy)quinolines bearing 1,2,3-triazole-4-carboxamide moiety as potent c-Met kinase inhibitors.
Liu M; Hou Y; Yin W; Zhou S; Qian P; Guo Z; Xu L; Zhao Y
Eur J Med Chem; 2016 Aug; 119():96-108. PubMed ID: 27155466
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel 4-phenoxyquinoline derivatives containing 3-oxo-3,4-dihydroquinoxaline moiety as c-Met kinase inhibitors.
Liu J; Yang D; Yang X; Nie M; Wu G; Wang Z; Li W; Liu Y; Gong P
Bioorg Med Chem; 2017 Aug; 25(16):4475-4486. PubMed ID: 28716639
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of novel 6,7-dimethoxy-4-anilinoquinolines as potent c-Met inhibitors.
Zhang QW; Ye ZD; Shen C; Tie HX; Wang L; Shi L
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):124-133. PubMed ID: 30422010
[TBL] [Abstract][Full Text] [Related]
10. Transforming Type II to Type I c-Met kinase inhibitors via combined scaffold hopping and structure-guided synthesis of new series of 1,3,4-thiadiazolo[2,3-c]-1,2,4-triazin-4-one derivatives.
El-Wakil MH; Teleb M
Bioorg Chem; 2021 Nov; 116():105304. PubMed ID: 34534756
[TBL] [Abstract][Full Text] [Related]
11. Design and Synthesis of Novel 4-Phenoxyquinolines Bearing 3-Hydrosulfonylacrylamido or 1H-Imidazole-4-carboxamido Scaffolds as c-Met Kinase Inhibitors.
Wang J; Xie L; Wang Y; Wang X; Xi S; Zeng T; Gong P; Zhai X
Arch Pharm (Weinheim); 2017 Feb; 350(2):. PubMed ID: 28133784
[TBL] [Abstract][Full Text] [Related]
12. Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2.
Shi W; Qiang H; Huang D; Bi X; Huang W; Qian H
Eur J Med Chem; 2018 Oct; 158():814-831. PubMed ID: 30248654
[TBL] [Abstract][Full Text] [Related]
13. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
Nan X; Li HJ; Fang SB; Li QY; Wu YC
Eur J Med Chem; 2020 May; 193():112241. PubMed ID: 32200199
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and pharmacological evaluation of 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents.
Zhou S; Ren J; Liu M; Ren L; Liu Y; Gong P
Bioorg Chem; 2014 Dec; 57():30-42. PubMed ID: 25173590
[TBL] [Abstract][Full Text] [Related]
15. Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.
Qi B; Mi B; Zhai X; Xu Z; Zhang X; Tian Z; Gong P
Bioorg Med Chem; 2013 Sep; 21(17):5246-60. PubMed ID: 23838381
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and structure-activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents.
Tang Q; Zhao Y; Du X; Chong L; Gong P; Guo C
Eur J Med Chem; 2013 Nov; 69():77-89. PubMed ID: 24012712
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel 1,2,4-triazolo-1,2,4-triazines with thiomethylpyridine hinge binders as potent c-Met kinase inhibitors.
Dadashpour S; Kϋçϋkkılınç TT; Ayazgök B; Hosseinimehr SJ; Chippindale AM; Foroumadi A; Irannejad H
Future Med Chem; 2019 May; 11(10):1119-1136. PubMed ID: 31280674
[No Abstract] [Full Text] [Related]
18. Design, Synthesis, and Biological Evaluation of 4-Phenoxyquinoline Derivatives Containing Benzo[d]thiazole-2-yl Urea as c-Met Kinase Inhibitors.
Lei H; Hu G; Wang Y; Han P; Liu Z; Zhao Y; Gong P
Arch Pharm (Weinheim); 2016 Aug; 349(8):651-61. PubMed ID: 27283017
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors.
Wang Z; Shi J; Zhu X; Zhao W; Gong Y; Hao X; Hou Y; Liu Y; Ding S; Liu J; Chen Y
Bioorg Chem; 2020 Dec; 105():104371. PubMed ID: 33075664
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives as selective c-Met inhibitors.
Wang X; Jiang N; Zhao S; Xi S; Wang J; Jing T; Zhang W; Guo M; Gong P; Zhai X
Bioorg Med Chem; 2017 Feb; 25(3):886-896. PubMed ID: 28011202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
